Arabic Arabic English English French French German German
dark

Eagle Pharmaceuticals Wins Vasopressin Patent Trial

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against the Company. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Advisory – Ivermectin not authorized to prevent or treat COVID-19; may cause serious health problems

Next Post

Harbour BioMed Reports 2021 Interim Results

Related Posts
Total
0
Share